Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
PGEN Stock Forecast 2026-2027
$4.41
Current Price
$1.56B
Market Cap
Buy 2
Hold 1
Sell 0
Wall St Analyst Ratings
Distance to PGEN Price Targets
+104.1%
To High Target of $9.00
+92.7%
To Median Target of $8.50
+81.4%
To Low Target of $8.00
PGEN Price Momentum
+6.5%
1 Week Change
+2.1%
1 Month Change
+297.3%
1 Year Change
+5.5%
Year-to-Date Change
-15.7%
From 52W High of $5.23
+308.3%
From 52W Low of $1.08
📊 TOP ANALYST CALLS
Did PGEN Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Precigen is one of their latest high-conviction picks.
Latest PGEN Stock Price Targets & Analyst Predictions
Based on our analysis of 7 Wall Street analysts, PGEN has a bullish consensus with a median price target of $8.50 (ranging from $8.00 to $9.00). The overall analyst rating is Strong Buy (8.0/10). Currently trading at $4.41, the median forecast implies a 92.7% upside. This outlook is supported by 2 Buy, 1 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Swayampakula Ramakanth at HC Wainwright & Co., projecting a 104.1% upside. Conversely, the most conservative target is provided by Jason N. Butler at JMP Securities, suggesting a 81.4% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
PGEN Analyst Ratings
2
Buy
1
Hold
0
Sell
PGEN Price Target Range
Low
$8.00
Average
$8.50
High
$9.00
Current: $4.41
Latest PGEN Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for PGEN.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Nov 14, 2025 | HC Wainwright & Co. | Swayampakula Ramakanth | Buy | Maintains | $9.00 |
| Aug 19, 2025 | JMP Securities | Jason N. Butler | Market Outperform | Maintains | $8.00 |
| Aug 19, 2025 | HC Wainwright & Co. | Swayampakula Ramakanth | Buy | Reiterates | $8.50 |
| Aug 15, 2025 | HC Wainwright & Co. | Swayampakula Ramakanth | Buy | Maintains | $8.50 |
| Aug 15, 2025 | JP Morgan | Brian Cheng | Neutral | Upgrade | $N/A |
| Aug 13, 2025 | HC Wainwright & Co. | Swayampakula Ramakanth | Buy | Reiterates | $6.00 |
| Jun 12, 2025 | JMP Securities | Jason Butler | Market Outperform | Reiterates | $6.00 |
| May 15, 2025 | Cantor Fitzgerald | Jennifer Kim | Overweight | Reiterates | $N/A |
| Mar 20, 2025 | Citizens Capital Markets | Jason Butler | Market Outperform | Reiterates | $6.00 |
| Mar 20, 2025 | HC Wainwright & Co. | Swayampakula Ramakanth | Buy | Reiterates | $6.00 |
| Jan 23, 2025 | HC Wainwright & Co. | Swayampakula Ramakanth | Buy | Reiterates | $6.00 |
| Jan 22, 2025 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Jan 14, 2025 | JMP Securities | Jason Butler | Market Outperform | Reiterates | $5.00 |
| Nov 15, 2024 | HC Wainwright & Co. | Swayampakula Ramakanth | Buy | Reiterates | $4.00 |
| Aug 15, 2024 | HC Wainwright & Co. | Swayampakula Ramakanth | Buy | Maintains | $4.00 |
| Aug 15, 2024 | JMP Securities | Jason Butler | Market Outperform | Maintains | $7.00 |
| Jun 4, 2024 | JMP Securities | Jason Butler | Market Outperform | Reiterates | $14.00 |
| Jun 3, 2024 | HC Wainwright & Co. | Swayampakula Ramakanth | Buy | Reiterates | $6.00 |
| Jun 3, 2024 | Stifel | Benjamin Burnett | Buy | Maintains | $10.00 |
| May 15, 2024 | Stifel | Benjamin Burnett | Buy | Maintains | $7.00 |
Precigen Inc. (PGEN) Competitors
The following stocks are similar to Precigen based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Precigen Inc. (PGEN) Financial Data
Precigen Inc. has a market capitalization of $1.56B with a P/E ratio of -9.4x. The company generates $6.31M in trailing twelve-month revenue with a -8.7% profit margin.
Revenue growth is +206.6% quarter-over-quarter, while maintaining an operating margin of -1,180.0% and return on equity of -507.7%.
Valuation Metrics
Market Cap
$1.56B
Enterprise Value
$1.54B
P/E Ratio
-9.4x
PEG Ratio
0.0x
Price/Sales
247.3x
Growth & Margins
Revenue Growth (YoY)
+206.6%
Gross Margin
+64.6%
Operating Margin
-1,180.0%
Net Margin
-8.7%
EPS Growth
+206.6%
Financial Health
Cash/Price Ratio
+7.8%
Current Ratio
4.0x
Debt/Equity
234.5x
ROE
-507.7%
ROA
-52.8%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Precigen Inc. (PGEN) Business Model
About Precigen Inc.
What They Do
Develops innovative gene therapies for diseases.
Business Model
The company generates revenue by developing and advancing gene therapies, particularly through its proprietary UltraCAR-T platform, which enhances the immune response against cancer. It also explores potential treatments for autoimmune disorders and infectious diseases, creating a diverse pipeline of therapeutic options that address significant medical needs.
Additional Information
Precigen Inc. is headquartered in Germantown, Maryland, and is focused on personalized medicine and precision therapies. Its commitment to pushing the boundaries of genetic science positions it as a key player in the biopharmaceutical sector.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
143
CEO
Dr. Helen Sabzevari MPH, Ph.D.
Country
United States
IPO Year
2019
Website
precigen.comPrecigen Inc. (PGEN) Latest News & Analysis
Latest News
Precigen, Inc. (PGEN) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
3 days ago
Quick Summary
Precigen, Inc. (PGEN) presented at the 44th Annual J.P. Morgan Healthcare Conference, highlighting key developments and strategies for investors.
Why It Matters
Precigen's presentation at a major healthcare conference signals potential developments in its pipeline, impacting investor sentiment and stock performance.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
Precigen has launched PAPZIMEOS, the first FDA-approved treatment for adults with RRP. Patient enrollment exceeds 200, and coverage now includes 170 million lives. European approval is pending.
Why It Matters
Precigen's FDA approval and rapid commercialization of PAPZIMEOS indicate strong market demand and revenue potential, enhancing investor confidence and attracting interest from health insurers.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Precigen, Inc. (Nasdaq: PGEN) will have its CEO, Dr. Helen Sabzevari, present at the 44th Annual J.P. Morgan Healthcare Conference on January 5, 2026.
Why It Matters
Helen Sabzevari's presentation at a prominent conference highlights Precigen's focus on innovative therapies, which could attract investor interest and impact stock performance.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Tang Capital Management acquired 12.4 million shares of Precigen, valued at $40.8 million, representing 1.6% of its assets. Precigen remains outside the fund's top five positions.
Why It Matters
Tang Capital's investment in Precigen indicates confidence in the company, potentially influencing market sentiment and stock performance, despite not being a top holding.
Source: The Motley Fool
Market Sentiment:
Positive
Quick Summary
Precigen (PGEN) retains a Buy rating after FDA approval of PAPZIMEOS, priced at ~$400,000 annually. A new credit facility extends cash runway to 2027, with breakeven targeted by 2026.
Why It Matters
Precigen's FDA approval of PAPZIMEOS and its high pricing enhance revenue prospects. The new credit facility extends cash runway, supporting growth and potential profitability by 2026.
Source: Seeking Alpha
Market Sentiment:
Positive
Quick Summary
Precigen, Inc. will hold its Q3 2025 earnings call on November 13, 2025, at 4:30 PM EST, featuring key executives discussing financial results and business updates.
Why It Matters
The earnings call provides insights into Precigen's financial performance and strategic direction, impacting stock valuation and investor sentiment. Key executives' updates can signal future growth potential.
Source: Seeking Alpha
Market Sentiment:
Neutral
Frequently Asked Questions About PGEN Stock
What is Precigen Inc.'s (PGEN) stock forecast for 2026?
Based on our analysis of 7 Wall Street analysts, Precigen Inc. (PGEN) has a median price target of $8.50. The highest price target is $9.00 and the lowest is $8.00.
Is PGEN stock a good investment in 2026?
According to current analyst ratings, PGEN has 2 Buy ratings, 1 Hold ratings, and 0 Sell ratings. The stock is currently trading at $4.41. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for PGEN stock?
Wall Street analysts predict PGEN stock could reach $8.50 in the next 12 months. This represents a 92.7% increase from the current price of $4.41. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Precigen Inc.'s business model?
The company generates revenue by developing and advancing gene therapies, particularly through its proprietary UltraCAR-T platform, which enhances the immune response against cancer. It also explores potential treatments for autoimmune disorders and infectious diseases, creating a diverse pipeline of therapeutic options that address significant medical needs.
What is the highest forecasted price for PGEN Precigen Inc.?
The highest price target for PGEN is $9.00 from Swayampakula Ramakanth at HC Wainwright & Co., which represents a 104.1% increase from the current price of $4.41.
What is the lowest forecasted price for PGEN Precigen Inc.?
The lowest price target for PGEN is $8.00 from Jason N. Butler at JMP Securities, which represents a 81.4% increase from the current price of $4.41.
What is the overall PGEN consensus from analysts for Precigen Inc.?
The overall analyst consensus for PGEN is bullish. Out of 7 Wall Street analysts, 2 rate it as Buy, 1 as Hold, and 0 as Sell, with a median price target of $8.50.
How accurate are PGEN stock price projections?
Stock price projections, including those for Precigen Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: January 19, 2026 12:34 AM UTC